Completed PHASE2 INTERVENTIONAL 2-arm NCT00004143

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes

Sponsor: David Rizzieri, MD

Conditions Paroxysmal Nocturnal Hemoglobinuria (PNH) Pure Red Cell Aplasia Severe Aplastic Anemia Sickle Cell Anemia

Interventions Campath, Chemo and/or TBI Allo SCT

Updated 9 times since 2017 Last updated: Nov 19, 2014 Started: Sep 30, 1999 Primary completion: May 31, 2008 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Paroxysmal Nocturnal Hemoglobinuria (PNH) and Pure Red Cell Aplasia and is currently completed. David Rizzieri, MD leads this study, which shows 9 recorded versions since 1999 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

David Rizzieri, MD

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States
• Orlando, United States